The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Leaders available to provide independent perspectives on health equity, artificial intelligence in healthcare, and the latest clinically relevant findings RYE BROOK, N.Y. Nov. 20, 2024 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) will present new data from its Beat AML® Master Clinical Trial and Pediatric Acute Leukemia (PedAL) Master Clinical Trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The findings from LLS's convened master clinical trials show great progress and are helping shape the treatment landscape for acute leukemias. Updated results show that more than half of a group of children with relapsed acute leukemias achieved remission after receiving a combination of treatments. Additional data indicate that IDH inhibitors as single agent or in combination with low-intensity therapies may be a viable treatment option for older adults with acute leukemias. LLS will also support its more than 150 funded researchers, as well as
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma plc (NASDAQ: RPRX) was upgraded by analysts at TD Cowen to a "strong-buy" rating.MarketBeat
- Royalty Pharma plc (NASDAQ:RPRX) is favoured by institutional owners who hold 72% of the company [Yahoo! Finance]Yahoo! Finance
- Lightning Round: M&T Bank is a buy, I like the banks, says Jim Cramer [CNBC]CNBC
- 3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer [Yahoo! Finance]Yahoo! Finance
- How Royalty Pharma, Open Text And VICI Properties Can Put Cash In Your Pocket [Yahoo! Finance]Yahoo! Finance
RPRX
Sec Filings
- 11/8/24 - Form SC
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- RPRX's page on the SEC website